Detail akcie Insight Molecular Diagnostics Inc online

Business Summary: Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Insight Molecular Diagnostics Inc revenues increased from $395K to $2.9M. Net loss applicable to common stockholders decreased 1% to $27.3M. Revenues reflect Pharma Services segment increase from $374K to $2.9M, Laboratory developed test services segment increase of 23% to $26K, United States Pharma services segment increase from $183K to $2.9M.